Aspire Biopharma Holdings Inc (ASBP)

Aug 13, 2026, 8:15 AM EDT - 11 days ago

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 19th

2026-08-10T12:35:26.000Z - 14 days ago

Aspire Biopharma completes acquisition of Dura Driver Control Systems

Aug 10, 2026, 8:30 AM EDT - 14 days ago

Aspire Biopharma Completes Acquisition of Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue

2026-07-29T16:30:42.000Z - 26 days ago

Aspire Biopharma Holdings Inc trading resumes

2026-07-29T16:25:47.000Z - 26 days ago

Aspire Biopharma Holdings Inc trading halted, volatility trading pause

2026-07-20T12:45:15.000Z - 5 weeks ago

Aspire Biopharma appoints Jarryd McNeil as sponsored athlete for BUZZ BOMB

Jul 20, 2026, 8:30 AM EDT - 5 weeks ago

Freestyle Motocross Legend Jarryd McNeil Named Newest Sponsored Athlete for Aspire Biopharma's BUZZ BOMB(TM)

Jun 24, 2026, 8:30 AM EDT - 2 months ago

Aspire Biopharma's BUZZ BOMB(TM) Launches on Amazon, Introducing Next-Generation Caffeine Stick Packs

TM

Jun 17, 2026, 10:57 AM EDT - 2 months ago

Aspire Biopharma to Present at the Life Sciences Investor Forum on June 25th

2026-06-12T18:20:26.000Z - 2 months ago

Aspire Biopharma Holdings Inc trading resumes

2026-06-12T18:10:38.000Z - 2 months ago

Aspire Biopharma Holdings Inc trading halted, volatility trading pause

2026-06-12T12:37:16.000Z - 2 months ago

Aspire Biopharma signs definitive SPA to acquire Dura Driver Control Systems

Jun 12, 2026, 8:30 AM EDT - 2 months ago

Aspire Biopharma Announces Signing of Definitive Share Purchase Agreement to Acquire Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue

2026-05-28T15:44:39.000Z - 3 months ago

Aspire Biopharma issues letter to shareholders

May 28, 2026, 8:30 AM EDT - 3 months ago

Aspire Biopharma Issues Shareholder Letter

2026-05-27T13:26:22.000Z - 3 months ago

Aspire Biopharma’s Buzz Bomb partners with EoS Fitness

May 27, 2026, 8:30 AM EDT - 3 months ago

Aspire Biopharma's BUZZ BOMBTM Partners with EoS Fitness to Empower High-Performance Lifestyles for Millions of Members

2026-05-08T23:50:15.000Z - 3 months ago

Aspire Biopharma Holdings Inc trading halted, news pending

2026-05-07T17:59:49.000Z - 3 months ago

Aspire Biopharma to effect 1-for-30 reverse stock split

May 7, 2026, 11:00 AM EDT - 3 months ago

Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split Ratio

2026-04-27T12:40:32.000Z - 4 months ago

Aspire Biopharma announces $5M share repurchase plan

Apr 27, 2026, 8:30 AM EDT - 4 months ago

Aspire Biopharma Announces $5.0 Million Share Repurchase Program

2026-04-20T14:15:12.000Z - 4 months ago

Aspire Biopharma closes final tranche of $21M private placement

Apr 20, 2026, 8:30 AM EDT - 4 months ago

Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS Acquisition

2026-04-17T12:15:44.000Z - 4 months ago

Buzz Bomb brand ambassador to attempt fastest 100-mile treadmill run

Apr 17, 2026, 8:00 AM EDT - 4 months ago

Aspire Biopharma's Buzz Bomb(TM) Caffeine Company's Brand Ambassador, Ashley Paulson, to Attempt Fastest 100-Mile Treadmill Run at 2026 Boston Marathon Expo

2026-04-16T12:48:21.000Z - 4 months ago

Aspire Biopharma enters LOI to acquire Dura Driver Control Systems for $30M

Apr 16, 2026, 8:30 AM EDT - 4 months ago

Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year History and $200M+ in 2025 Revenue

2026-04-15T12:22:20.000Z - 4 months ago

Aspire Biopharma subsidiary announce sales, marketing agreement with Interwest

Apr 15, 2026, 8:00 AM EDT - 4 months ago

Aspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail Expansion

2026-03-19T12:57:13.000Z - 5 months ago

Aspire Biopharma subsidiary signs retail distribution agreement with TruLife

Mar 19, 2026, 8:00 AM EDT - 5 months ago

Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion

Mar 17, 2026, 8:30 AM EDT - 5 months ago

Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director

Mar 12, 2026, 8:00 AM EDT - 5 months ago

Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026

2026-03-10T12:51:37.000Z - 5 months ago

Aspire Biopharma launches BUZZ BOMB Covenience Store Pack

Mar 10, 2026, 8:30 AM EDT - 5 months ago

Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack

2026-03-03T13:30:58.000Z - 6 months ago

Aspire Biopharma, Microsize partner for sublingual alprazolam formulation

Mar 3, 2026, 8:00 AM EST - 6 months ago

Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief

Feb 25, 2026, 8:30 AM EST - 6 months ago

Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship

Feb 20, 2026, 8:00 AM EST - 6 months ago

Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements

Feb 19, 2026, 8:00 AM EST - 6 months ago

Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record

Feb 17, 2026, 8:30 AM EST - 6 months ago

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))

Feb 13, 2026, 8:00 AM EST - 6 months ago

Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors

Feb 12, 2026, 8:00 AM EST - 6 months ago

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))

Feb 11, 2026, 7:45 AM EST - 6 months ago

Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements

Feb 10, 2026, 8:00 AM EST - 6 months ago

Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 5, 2026, 8:00 AM EST - 7 months ago

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit

Feb 3, 2026, 8:00 AM EST - 7 months ago

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution

Jan 29, 2026, 8:00 AM EST - 7 months ago

Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin

Jan 27, 2026, 8:00 AM EST - 7 months ago

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel (Generic Plavix(R)) to Address Gastric Bleeding Risks

Jan 22, 2026, 8:00 AM EST - 7 months ago

Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity

Jan 21, 2026, 8:00 AM EST - 7 months ago

Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign

Jan 20, 2026, 8:00 AM EST - 7 months ago

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief

Jan 14, 2026, 8:00 AM EST - 7 months ago

Aspire Biopharma Announces Reverse Stock Split

Jan 7, 2026, 8:00 AM EST - 8 months ago

Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)

Dec 18, 2025, 8:30 AM EST - 8 months ago

Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine

Dec 12, 2025, 5:00 PM EST - 9 months ago

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Dec 4, 2025, 9:00 AM EST - 9 months ago

Aspire Biopharma Provides Q3 2025 Business Update

Dec 2, 2025, 9:00 AM EST - 9 months ago

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Nov 26, 2025, 9:00 AM EST - 9 months ago

Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member

Nov 6, 2025, 9:00 AM EST - 10 months ago

Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin

Oct 6, 2025, 8:30 AM EDT - 11 months ago

Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform

Oct 3, 2025, 11:30 AM EDT - 11 months ago

Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025

Oct 1, 2025, 8:30 AM EDT - 11 months ago

Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication

Sep 17, 2025, 8:30 AM EDT - 1 year ago

Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product

Sep 16, 2025, 8:30 AM EDT - 1 year ago

Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement

Sep 3, 2025, 8:30 AM EDT - 1 year ago

Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aug 18, 2025, 8:30 AM EDT - 1 year ago

Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aug 14, 2025, 8:00 AM EDT - 1 year ago

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20